Pictet Asset Management
RXRX icon

Pictet Asset Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Pictet Asset Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$258K Hold
70,303
– – ﹤0.01% 1848
2026
Q1 		$216K Buy
70,303
+27,820
+65% +$108K ﹤0.01% 1905
2025
Q4 		$174K Hold
42,483
– – ﹤0.01% 1956
2025
Q3 		$207K Buy
42,483
+7,086
+20% +$37.2K ﹤0.01% 1855
2025
Q2 		$179K Hold
35,397
– – ﹤0.01% 1851
2025
Q1 		$187K Hold
35,397
– – ﹤0.01% 1808
2024
Q4 		$239K Buy
35,397
+13,066
+59% +$87.8K ﹤0.01% 1768
2024
Q3 		$147K Hold
22,331
– – ﹤0.01% 1897
2024
Q2 		$167K Hold
22,331
– – ﹤0.01% 1800
2024
Q1 		$223K Buy
22,331
+7,344
+49% +$81.8K ﹤0.01% 1716
2023
Q4 		$148K Hold
14,987
– – ﹤0.01% 1807
2023
Q3 		$115K Buy
+14,987
New +$150K ﹤0.01% 1810

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Pictet Asset Management's RXRX Position: Q2 2026 in Review

Pictet Asset Management held its Recursion Pharmaceuticals (RXRX) position steady in Q2 2026 at 70,303 shares worth $258K. The position accounts for ﹤0.01% of the portfolio, ranked #1848.

Pictet Asset Management first reported a position in RXRX in Q3 2023 and has held it in 12 quarters since. 170 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Pictet Asset Management held 70,303 shares of Recursion Pharmaceuticals worth $258K as of Q2 2026.
  • Pictet Asset Management left its Recursion Pharmaceuticals share count unchanged in Q2 2026.
  • Recursion Pharmaceuticals made up ﹤0.01% of Pictet Asset Management's portfolio in Q2 2026, its #1848 holding.
  • Pictet Asset Management first reported a position in Recursion Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
  • 170 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Pictet Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.